Christopher J Nicolai
Overview
Explore the profile of Christopher J Nicolai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danielson M, Nicolai C, Vo T, Wolf N, Burke T
iScience
. 2024 Dec;
27(12):111385.
PMID: 39669426
Intracellular bacterial pathogens are distinctive tools for fighting cancer, as they can proliferate in tumors and deliver therapeutic payloads to the eukaryotic cytosol. Cytosol-dwelling bacteria have undergone extensive preclinical and...
2.
Nicolai C, Parker M, Qin J, Tang W, Ulrich-Lewis J, Gottschalk R, et al.
Blood
. 2024 Jun;
144(9):977-987.
PMID: 38861668
Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformative efficacy in treating B-cell malignancies. However, high costs and manufacturing complexities hinder their widespread use. To overcome these hurdles, we have...
3.
Michels K, Sheih A, Hernandez S, Brandes A, Parrilla D, Irwin B, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36918221
Background: Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with...
4.
Wolf N, Blaj C, Picton L, Snyder G, Zhang L, Nicolai C, et al.
Proc Natl Acad Sci U S A
. 2022 May;
119(22):e2200568119.
PMID: 35588144
Cyclic dinucleotides (CDN) and Toll-like receptor (TLR) ligands mobilize antitumor responses by natural killer (NK) cells and T cells, potentially serving as complementary therapies to immune checkpoint therapy. In the...
5.
Kim J, Chuang H, Wolf N, Nicolai C, Raulet D, Saijo K, et al.
Dev Cell
. 2021 Sep;
56(19):2712-2721.e4.
PMID: 34496290
Cancer patients often die from symptoms that manifest at a distance from any tumor. Mechanisms underlying these systemic physiological perturbations, called paraneoplastic syndromes, may benefit from investigation in non-mammalian systems....
6.
Tang K, Dong K, Nicolai C, Li Y, Li J, Lou S, et al.
Sci Adv
. 2020 Dec;
6(50).
PMID: 33298452
Thermography detects surface temperature and subsurface thermal activity of an object based on the Stefan-Boltzmann law. Impacts of the technology would be more far-reaching with finer thermal sensitivity, called noise-equivalent...
7.
8.
Nicolai C, Wolf N, Chang I, Kirn G, Marcus A, Ndubaku C, et al.
Sci Immunol
. 2020 Mar;
5(45).
PMID: 32198222
Several immunotherapy approaches that mobilize CD8 T cell responses stimulate tumor rejection, and some, such as checkpoint blockade, have been approved for several cancer indications and show impressive increases in...
9.
De Leon J, Qiu J, Nicolai C, Counihan J, Barry K, Xu L, et al.
Cell Rep
. 2017 Nov;
21(8):2031-2038.
PMID: 29166595
All pathogens must acquire nutrients from their hosts. The intracellular bacterial pathogen Legionella pneumophila, the etiological agent of Legionnaires' disease, requires host amino acids for growth within cells. The mechanistic...
10.
Farley D, McCloskey L, Thorne B, Tareen S, Nicolai C, Campbell D, et al.
Mol Ther Methods Clin Dev
. 2015 Jun;
2:15017.
PMID: 26029728
It is a current regulatory requirement to demonstrate absence of detectable replication-competent lentivirus (RCL) in lentiviral vector products prior to use in clinical trials. Immune Design previously described an HIV-1-based...